Stem Cell Mobilization in Diabetic Neuropathy Subjects Receiving SB-509

NCT00665145 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

23

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 1
Diabetes Mellitus, Type 2
Diabetic Polyneuropathy

Interventions

DRUG: SB-509
DRUG: SB-509
DRUG: Placebo
DRUG: SB-509

Sponsor

Sangamo Therapeutics